Columbia University Vagelos College of Physicians and Surgeons

ProMIS appoints experienced industry veteran Larry Altstiel as Chief Medical Officer

Retrieved on: 
Tuesday, April 19, 2022
Protein, ALS, CEO, Columbia University Vagelos College of Physicians and Surgeons, Columbia University College of Dental Medicine, Neurodegeneration, Neuroscience, Parkinson's disease, Cell biology, Montreal Neurological Institute and Hospital, Intention, Toronto Stock Exchange, Rockefeller University, Doctor of Philosophy, GLOBE, Pfizer, PROMIS, Amyotrophic lateral sclerosis, Virology, Technology, Company, Disease, Method, AD, Harvard University, TSX, Epitope, PMN, University, Physician, Surgeon, Therapy, PD, Alzheimer's disease, Pharmaceutical industry, Neurology

Larry Altstiel has been a respected leader for over twenty years in the Alzheimers clinical research community, and we are delighted to welcome him to the ProMIS team, stated Gene Williams, ProMIS Chairman and CEO.

Key Points: 
  • Larry Altstiel has been a respected leader for over twenty years in the Alzheimers clinical research community, and we are delighted to welcome him to the ProMIS team, stated Gene Williams, ProMIS Chairman and CEO.
  • ProMIS has shown compelling scientific rationale for the differentiation of PMN310 in Alzheimers disease according to Dr. Altstiel.
  • ProMIS unique technology platform has also led to the generation of potentially differentiated therapies in ALS and other neurodegenerative diseases.
  • Larry Altstiel, M.D., Ph.D. brings decades of medical expertise in neurodegenerative diseases and experience in the pharmaceutical industry.

Dr. Anekwe E. Onwuanyi Installed as President of the Association of Black Cardiologists

Retrieved on: 
Wednesday, April 13, 2022
Board, Columbia University Vagelos College of Physicians and Surgeons, Grady Memorial Hospital, Columbia University College of Dental Medicine, Morehouse School of Medicine, Health equity, COVID-19, Association, ABC, Research, MSM, Leadership, Doctor of Philosophy, Education, Cardiology, Chairperson, Workforce, Mortality, Community health, Association of Black Cardiologists, Capacity building, Spirit, Color, History, Director, FACC, Assistant, CVD, Physician, Risk, Mount Sinai School, Surgeon, Cardiovascular disease, ABC Board, MPH, Television, Pharmaceutical industry, MD, Medicine

WASHINGTON, April 13, 2022 /PRNewswire/ -- Anekwe E. Onwuanyi, MD, FACC , was installed as the 19th President of the Association of Black Cardiologists (ABC) during the Spring 2022 Membership Meeting.

Key Points: 
  • WASHINGTON, April 13, 2022 /PRNewswire/ -- Anekwe E. Onwuanyi, MD, FACC , was installed as the 19th President of the Association of Black Cardiologists (ABC) during the Spring 2022 Membership Meeting.
  • He is the first board-certified, advanced heart failure specialist to hold the position in ABC's nearly 50-year history.
  • A dedicated life member of the ABC, Dr. Onwuanyi has been active with the organization for more than 30 years.
  • "It is the honor of a lifetime to have been entrusted by the membership to take the reins of the association we love," says Dr. Onwuanyi.

Cara Therapeutics Announces Biomarker Data from KALM-1 and KALM-2 Trials of KORSUVA™ (difelikefalin) Injection Selected for Presentation at National Kidney Foundation Spring Clinical Meetings 2022

Retrieved on: 
Monday, April 4, 2022
Chronic kidney disease, Moderate, Company, National Kidney Foundation, Therapy, LinkedIn, Primary biliary cholangitis, Physician, Columbia University Vagelos College of Physicians and Surgeons, Oral, Columbia University College of Dental Medicine, Itch, Poster, MD, Twitter, Nasdaq, CKD, GLOBE, Sleep, Trial of the century, FDA, Instagram, Atopic dermatitis, Pharmaceutical industry, Paint, Patient, Surgeon

Details for the poster presentation are as follows:

Key Points: 
  • Details for the poster presentation are as follows:
    Presenter: Shayan Shirazian, MD, Columbia University College of Physicians and Surgeons, New York, NY
    The ePoster is available at: https://www.kidney.org/spring-clinical .
  • The Companys novel KORSUVA (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
  • Phase 2 trials of Oral KORSUVA (difelikefalin) are ongoing in primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.
  • For more information, visit www.CaraTherapeutics.com and follow the company on Twitter , LinkedIn and Instagram .

ReCor Medical Announces Completion of Enrollment in RADIANCE-II Pivotal Trial of the Paradise™ Ultrasound Renal Denervation System for the Treatment of Uncontrolled Hypertension

Retrieved on: 
Tuesday, March 29, 2022
Medical Devices, Health, Clinical Trials, Radiology, Cardiology, Biotechnology, Hypertension, CE, Mortality, Patient, Tokyo Stock Exchange, Physician, Columbia University, Publication, Hospital, TRIO, NewYork-Presbyterian Hospital, ReCore, Safety, Columbia University Vagelos College of Physicians and Surgeons, BP, CA, COVID-19, Disease, SOLO, Surgeon, FDA, System, PMA, Registry, Pharmaceutical industry, Medicine, EU, RECOR MEDICAL, INC., OTSUKA MEDICAL DEVICES CO., LTD.

ReCor Medical, Inc. (ReCor), a fully owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today completion of enrollment in their RADIANCE-II pivotal trial of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of uncontrolled hypertension.

Key Points: 
  • ReCor Medical, Inc. (ReCor), a fully owned subsidiary of Otsuka Medical Devices Co., Ltd., announced today completion of enrollment in their RADIANCE-II pivotal trial of the Paradise Ultrasound Renal Denervation (uRDN) System for the treatment of uncontrolled hypertension.
  • The RADIANCE-II pivotal trial is a randomized, sham-controlled clinical trial of ReCors Paradise uRDN System for the treatment of uncontrolled hypertension in patients on zero-to-two antihypertensive oral medications.
  • The RADIANCE-II pivotal trial was carefully designed to assess the BP-lowering efficacy and safety of treating uncontrolled hypertension with the Paradise uRDN System.
  • ReCor has pioneered the minimally invasive use of ultrasound in renal denervation, and developed the Paradise System, to treat patients with hypertension.

Vaxxinity Appoints Dr. Peter Powchik to Board of Directors

Retrieved on: 
Monday, March 21, 2022
Private Securities Litigation Reform Act, Company, Drug development, Chugai Pharmaceutical Co., Conditional sentence, Mount Sinai Medical Center, Board, Migraine, Physician, Columbia University Vagelos College of Physicians and Surgeons, New York University Grossman School of Medicine, Vaccine, Columbia University College of Dental Medicine, Risk, PCSK9, Novartis, Hypercholesterolemia, Health, U.S. Securities and Exchange Commission, Board of directors, Technology, Nasdaq, COVID-19, Licensure, GLOBE, Regeneron Pharmaceuticals, Drug, Surgeon, Research and development, Efficiency, Social media, Patient, Disease, Security (finance), Pharmaceutical industry, Sunovion, Director

is joining its Board of Directors and will be retiring as Vaxxinitys Executive Vice President, Research & Development.

Key Points: 
  • is joining its Board of Directors and will be retiring as Vaxxinitys Executive Vice President, Research & Development.
  • This transition will be effective March 31, 2022 and will increase the size of the Board to seven.
  • We are fortunate to have him joining our Board where we may continue to leverage his considerable expertise to develop vaccines and treat chronic diseases, said Lou Reese, Executive Chairman of Vaxxinity.
  • We thank Peter for his outstanding contribution to Vaxxinity and warmly welcome him to our Board of Directors, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022
Doctor of Philosophy, MD, Depression, Technology, Associate, Patient, Schizophrenia, Oklahoma Medical Research Foundation, CNS, Columbia University Vagelos College of Physicians and Surgeons, Therapy, Post-traumatic stress disorder, Data, Columbia University, Parkinson's disease, Brain, Neuropsychiatry, Physician, Algorithm, Addiction, Biomarker, Alzheimer's disease, PTSD, Research, Mental Hygiene, CEO, Pharmaceutical industry, Terran, Surgeon

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Terran Biosciences announces licensing deal with Columbia University for exclusive worldwide rights to proprietary CNS biomarker software platform

Retrieved on: 
Wednesday, March 16, 2022
Doctor of Philosophy, MD, Depression, Technology, Associate, Patient, Schizophrenia, Oklahoma Medical Research Foundation, CNS, Columbia University Vagelos College of Physicians and Surgeons, Therapy, Post-traumatic stress disorder, Data, Columbia University, Parkinson's disease, Brain, Neuropsychiatry, Physician, Algorithm, Addiction, Biomarker, Alzheimer's disease, PTSD, Research, Mental Hygiene, CEO, Pharmaceutical industry, Terran, Surgeon

NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.

Key Points: 
  • NEW YORK, March 16, 2022 /PRNewswire/ -- Terran Biosciences, Inc. ("Terran"), a biotech platform company dedicated to the development of transformational therapeutics and technologies for neurological and psychiatric diseases, has entered into an agreement with Columbia University ("Columbia") and the Research Foundation for Mental Hygiene ("RFMH"), to obtain worldwide exclusive rights to develop and commercialize Columbia's proprietary CNS biomarker software platform and patent portfolio.
  • The foundational algorithms were initially developed by a team of Columbia physicians, neuroscientists, and software engineers, led by Guillermo Horga, MD, PhD, and Clifford Cassidy, PhD.
  • On the back of this data, Terran is further developing the algorithms by incorporating them into Terran's cloud-based software as a medical device (SaMD) platform.
  • Terran is a biotech platform company developing a portfolio of therapeutics and technologies for patients with neurological and psychiatric diseases.

Stablix Names Tony Kingsley CEO

Retrieved on: 
Monday, February 14, 2022
Biotechnology, Pharmaceutical, Health, Other Health, Biogen, Physiology, Dartmouth College, CEO, Degenerative disease, COO, Company, Harvard Business School, Sequah Medicine Company, NEA, Investment, McKinsey & Company, Protein, Columbia University Vagelos College of Physicians and Surgeons, TPS, Gongshi, Dub, Ubiquitin, MBA, Drug development, Management, Pharmacology

Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Tony Kingsley as Chief Executive Officer.

Key Points: 
  • Stablix, Inc., a biopharmaceutical company pioneering targeted protein stabilization (TPS) as a novel therapeutic modality, today announced the appointment of Tony Kingsley as Chief Executive Officer.
  • Mr. Kingsley replaces interim CEO Dr. Carlo Rizzuto, partner at founding investor Versant Ventures, who remains on Stablixs board of directors.
  • Mr. Kingsley is an experienced biotech CEO with a track record leading and building organizations across multiple scientific disciplines, therapeutic areas and stages of drug development.
  • Earlier in his career, Mr. Kingsley held leadership roles in the medical device and diagnostics industries and was a partner at McKinsey & Company.

CarePoint Health Partners with Columbia University to Enhance Colorectal Services

Retrieved on: 
Wednesday, February 9, 2022
School, Columbia University Vagelos College of Physicians and Surgeons, Multimedia, Columbia School of Linguistics, Columbia University Mailman School of Public Health, Division, Columbia University Irving Medical Center, Innovation, Hoboken University Medical Center, NEW, Dentistry, Quality of life, Bayonne Medical Center, Patient, Technology, CEO, Physician, Columbia College, Health, Nursing, Center, Research, Colorectal surgery, Fortis Healthcare, Partnership, Columbia University, Public health, Christ Hospital, Hospital, Medicine, Surgeon

This collaboration will help elevate our ability to offer care across the CarePoint system," said Dr. Achintya Moulick, CEO CarePoint Health.

Key Points: 
  • This collaboration will help elevate our ability to offer care across the CarePoint system," said Dr. Achintya Moulick, CEO CarePoint Health.
  • "CarePoint continues to focus on patient-focused health care froman extensive network of specialists,which now includes highly experienced surgeons focused on colorectal conditions."
  • CarePoint is a dedicated and innovative health care leader providing excellent care to its patients across the region.
  • Beyond patient care, Columbia University Irving Medical Center stands as one of the top academic medical centers in the world.

Applaud Medical Receives FDA Breakthrough Device Designation for the Company’s Acoustic Enhancer for Use in Conjunction With Ureteroscopy With Laser Lithotripsy (URS-LL) for the Fragmentation of Calcium-Based Kidney Stones

Retrieved on: 
Monday, January 31, 2022
Research, Medical Devices, FDA, Clinical Trials, Other Health, Health, General Health, Other Science, Science, Entrepreneurship, Erosion, Risk, Kidney, Acoustic enhancement, Patient, Laser lithotripsy, Food, Dyslipidemia, Medicine, Ureteroscopy, Columbia University Vagelos College of Physicians and Surgeons, Obstruction, Technology, Chronic kidney disease, Diabetes, Prevalence, Company, Incidence, Applause, Hypertension, Columbia University Irving Medical Center, Doctor of Philosophy, Sepsis, Obesity, Physician, Columbia University College of Dental Medicine, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Division, FDA, Urologic disease, Medical imaging, Pharmaceutical industry, Urology, Surgeon

Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced that its Acoustic Enhancer technology has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

Key Points: 
  • Applaud Medical, Inc. (Applaud), an emerging leader in the treatment of kidney stones, today announced that its Acoustic Enhancer technology has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).
  • The Acoustic Enhancer microparticles generate additional stone-fragmenting shockwaves when used during a laser lithotripsy procedure.
  • The Company is developing the Applaud Acoustic Enhancer, an innovative technology designed to enhance URS-LL in the fragmentation of kidney stones.
  • The Company is also actively conducting a prospective, multicenter, randomized, double-blind study ( NCT04563039 ) for the Acoustic Enhancer when used in conjunction with URS-LL.